Recently adopted names for antitumoral compounds (February 2013) - Noms d’antitumoraux adoptés récemment (février 2013)

Name (nom)	Code name	Type	Target(s)
Galunisertib	LY2157299	synthetic small inhibitor	TGF-βR1 TGF-βR2
Margetuximab	MGAH22	monoclonal antibody	ERBB2
Palbociclib	PD-0332991	synthetic small inhibitor	CDK4 and CDK6
Pevonedistat	MLN-4924	synthetic small inhibitor	Nedd8 activating enzyme
Tovetumab	MEDI-575	monoclonal antibody	PDGFRα
Vantictumab	OMP-18R5	monoclonal antibody	Frizzled